Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
Conditions
- Colorectal Cancer Metastatic
Interventions
- BIOLOGICAL: FOLFIRI-cetuximab
- BIOLOGICAL: mFOLFOX6-bevacizumab
- BIOLOGICAL: OPTIMOX-bevacizumab
- BIOLOGICAL: irinotecan-based chemo + bevacizumab
- BIOLOGICAL: Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)
- BIOLOGICAL: XELOX + bevacizumab
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborators